Geburtshilfe Frauenheilkd 2011; 71 - O_17
DOI: 10.1055/s-0031-1286472

Seröses carcinoma in situ und p53-Signatur beim primären Tubenkarzinom und primären Peritonealkarzinom

K Leonhardt 1, J Einenkel 2, K Engeland 2, C Soor 2, LC Horn 1
  • 1Institute of Pathology, Division of Breast, Gynecologic & Perinatal Pathology, University of Leipzig
  • 2Department of Obstetrics and Gynecology (Institute of Trier), Division of Molecular Gynecologic Oncology, University of Leipzig

Fragestellung:

Serous tubal in situ carcinoma (STIC) has been defined as one important precursor of pelvic serous cancer (Folkins et al. 2008, Crum 2009, Lynch et al. 2009). Morphologically, STIC is defined by are cytologic atypia, high proliferative index and strong staining for p53 (Jarboe et al. 2008). Recently, STIC has been reported in about 30% of endometrial serous carcinomas (Jarboe et al. 2009). As a precursor lesion of STIC, characterised by low proliferative index, but p53-accumulation and no cytologic atypia has been defined (Lee et al. 2007).

Methode:

The present study evaluates the presence of STIC and p53-signature in consecutive cases of 12 prophylactic salpingo-oophorectomy in women with BRCA-1-mutaion (BSO), 11 macroscopically inconspicuous tubes of patients with primary tubal cancer (TC) and 9 cases of primary peritoneal cancer (PPC) using immunohistochemistry against Ki-67 and p53 (clone DO-7).

Ergebnisse:

The frequency of p53-signature and STIC was 8% and 0% in cases of prophylactic surgery, 9% and 18% in TC and 0% and 33% in PPC.

Schlussfolgerung:

STIC and p53-signature as precursor lesions of pelvic serous cancer is seen in macroscopically inconspicuous Fallopian tubes in unilateral TC in patients with elective BSO and patients affected by PPC. We propose that the sectioning and extensively examining the fimbria protocol be applied to all cases with PPC, TC and in women with prophylactic BSO.